Novel Antimicrobial Peptides: Targeting Wound Infections Caused by ‘Superbugs’ Resistant to All Current Antibiotics

2017 ◽  
pp. 203-211
Author(s):  
Tony Velkov ◽  
Chongyu Zhu ◽  
David M. Haddleton ◽  
Jian Li
Keyword(s):  
Antimicrobial Peptides ◽  
Wound Infections

scholarly journals Designed Antimicrobial Peptides Against Trauma-Related Cutaneous Invasive Fungal Wound Infections

2020 ◽  
Vol 6 (3) ◽  
pp. 184
Author(s):  
Kathryn W. Woodburn ◽  
Jesse M. Jaynes ◽  
L. Edward Clemens
Keyword(s):  
Antimicrobial Peptides ◽  
Broad Spectrum ◽  
Clinical Care ◽  
Structural Analog ◽  
Wound Infections ◽  
First Line ◽  
Empiric Treatment ◽  
Patients At Risk ◽  
Life Threatening ◽  
Traumatic Wound

Cutaneous invasive fungal wound infections after life-threatening dismounted complex blast injury (DCBI) and natural disasters complicate clinical care. These wounds often require aggressive repeated surgical debridement, can result in amputations and hemipelvectomies and have a 38% mortality rate. Given the substantial morbidity associated with cutaneous fungal wound infections, patients at risk need immediate empiric treatment mandating the use of rapidly acting broad-spectrum antimicrobials, acting on both fungi and bacteria, that are also effective against biofilm and can be administered topically. Designed antimicrobial peptides (dAMPs) are engineered analogues of innate antimicrobial peptides which provide the first line of defense against invading pathogens. The antifungal and antibacterial effect and mammalian cytotoxicity of seven innovative dAMPs, created by iterative structural analog revisions and physicochemical and functional testing were investigated. The dAMPs possess broad-spectrum antifungal activity, in addition to being effective against Gram-negative and Gram-positive bacteria, which is crucial as many wounds are polymicrobial and require immediate empiric treatment. Three of the most potent dAMPs—RP504, RP556 and RP557—possess limited mammalian cytotoxicity following 8 h incubation. If these encouraging broad-spectrum antimicrobial and rapid acting results are translated clinically, these novel dAMPs may become a first line empiric topical treatment for traumatic wound injuries.

scholarly journals Short Synthetic β-Sheet Antimicrobial Peptides for the Treatment of Multidrug-ResistantPseudomonas aeruginosaBurn Wound Infections

2017 ◽  
Vol 6 (7) ◽  
pp. 1601134 ◽  
Author(s):  
Guansheng Zhong ◽  
Junchi Cheng ◽  
Zhen Chang Liang ◽  
Liang Xu ◽  
Weiyang Lou ◽  
...  
Keyword(s):  
Antimicrobial Peptides ◽  
Wound Infections ◽  
Β Sheet

scholarly journals An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

Pharmaceutics ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 840 ◽  
Author(s):  
Viorica Patrulea ◽  
Gerrit Borchard ◽  
Olivier Jordan
Keyword(s):  
Antimicrobial Peptides ◽  
Bacterial Infections ◽  
Antimicrobial Agents ◽  
New Technologies ◽  
Multidrug Resistant ◽  
Inorganic Nanoparticles ◽  
Wound Dressings ◽  
Wound Infections ◽  
Clinical Phase ◽  
Delivery Strategies

Bacterial infections occur when wound healing fails to reach the final stage of healing, which is usually hindered by the presence of different pathogens. Different topical antimicrobial agents are used to inhibit bacterial growth due to antibiotic failure in reaching the infected site, which is accompanied very often by increased drug resistance and other side effects. In this review, we focus on antimicrobial peptides (AMPs), especially those with a high potential of efficacy against multidrug-resistant and biofilm-forming bacteria and fungi present in wound infections. Currently, different AMPs undergo preclinical and clinical phase to combat infection-related diseases. AMP dendrimers (AMPDs) have been mentioned as potent microbial agents. Various AMP delivery strategies that are used to combat infection and modulate the healing rate—such as polymers, scaffolds, films and wound dressings, and organic and inorganic nanoparticles—have been discussed as well. New technologies such as Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated protein (CRISPR-Cas) are taken into consideration as potential future tools for AMP delivery in skin therapy.

scholarly journals An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections

2020 ◽  
Author(s):  
Viorica Patrulea ◽  
Gerrit Borchard ◽  
Olivier Jordan
Keyword(s):  
Antimicrobial Peptides ◽  
Bacterial Infections ◽  
Antimicrobial Agents ◽  
New Technologies ◽  
Multidrug Resistant ◽  
Inorganic Nanoparticles ◽  
Wound Dressings ◽  
Wound Infections ◽  
Clinical Phase ◽  
Delivery Strategies

Bacterial infections occur when wound healing fails to reach the final stage of healing, usually hindered by the presence of different pathogens. Different topical antimicrobial agents are used to inhibit bacterial growth due to antibiotic failure in reaching the infected site accompanied very often by an increased drug resistance and other side effects. In this review, we focus on antimicrobial peptides (AMPs), especially those with a high potential of efficacy against multidrug-resistant and biofilm-forming bacteria and fungi present in wound infections. Currently, different AMPs undergo preclinical and clinical phase to combat infection-related diseases. AMP dendrimers (AMPDs) have been mentioned as potent microbial agents. Various AMP delivery strategies, such as polymers, scaffolds, films and wound dressings, organic and inorganic nanoparticles, to combat infection and modulate the healing rate have been discussed as well. New technologies such as CRISPR-Cas are taken into consideration as potential future tools for AMP delivery in skin therapy.

Antimicrobial peptides in COPD

Pneumologie ◽  
2009 ◽  
Vol 63 (S 01) ◽  
Author(s):  
G Günther ◽  
E Andresen ◽  
J Bullwinkel ◽  
C Lange ◽  
H Heine
Keyword(s):  
Antimicrobial Peptides
Sign in / Sign up

Export Citation Format

Share Document